Table 1 Characteristics of study sample
From: Use of Remdesivir in children with COVID-19: report of an Italian multicenter study
Total | 50 | NA |
|---|---|---|
Males - n (%) | 32 (64) | 0 |
Weight (kg) - median ± IQR (range) | 65.5 ± 47.5 (3.2–130) | 9 |
Age (years) - median ± IQR (range) | 12.8 ± 5.2 (0.02–17.5) | 2 |
Hospitalization (days) - median ± IQR (range) PICU admission - n (%) PICU admission (days) | 12 ± 14 (2–63) 16 (34) 15 ± 18 (2–27) | 6 3 2 |
Comorbidities - n (%) Obesity Neurological disorder Immunodeficiency Pulmonary or thoracic condition Congenital disorder Other | 39 (78) 11 (28) 9 (23) 8 (21) 3 (8) 4 (10) 4 (10) | 0 |
Concomitant therapies - n (%) | 13 (30) | 6 |
Symptoms - n (%) | 0 | |
Fever Temperature (°C, max value) - median ± IQR (range) Cough Dyspnea Rhinorrhea Sore throat Chest pain Diarrhea Abdominal pain Vomiting Fatigue Anorexia Headache Joint/muscle pain Dysgeusia/anosmia Hypotonia Rash Seizures Conjunctivitis | 44 (88) 39 ± 1.0 (36.0–40.8) 37 (74) 34 (68) 10 (20) 11 (22) 7 (14) 7 (14) 6 (12) 6 (12) 5 (10) 4 (8) 4 (8) 3 (6) 2 (4) 2 (4) 2 (4) 2 (4) 1 (2) | - 4 - - - - - - - - - - - - - - - - - |
Complications - n (%) Pneumonia Viral Bacterial Mixed Acute respiratory failure ARDS MIS-C | 32 (76) 48 (96) 25 (63) 2 (5) 13 (33) 29 (58) 10 (21) 3 (6) | 8 0 - - - 0 2 0 |
Administration of O2 - n (%) Mask/nasal cannulae Mask/nasal cannulae (days)** High-flow nasal cannulae - HFNC High-flow nasal cannulae - HFNC (days)** Non-invasive ventilation - NIV Non-invasive ventilation - NIV (days)** Mechanical ventilation Mechanical ventilation (days)** Extra-Corporeal Membrane Oxygenation - ECMO Extra-Corporeal Membrane Oxygenation - ECMO** Total duration of O2 administration/ventilation (days)** | 38 (78) 31 (63) 4 ± 3 15 (38) 6 ± 8 (1–25) 12 (25) 4.5 ± 6 (1–14) 7 (14) 16 ± 14 (3–23) 2 (5) 9.5 ± / (2–17) 3 ± 7 (0–27) | 1 1 10 11 4 2 2 1 2 11 0 1 |
Laboratory workup | ||
Leukocytosis - n (%) Leukopenia - n (%) Increased PCR - n (%) Increased PCT - n (%) Bacterial coinfection - n (%) | 8 (18) 27 (66) 31(63) 6 (15) 9 (22) | 6 9 1 10 9 |
Clinical outcome | ||
Recovery without sequelae - n (%) Death - n (%) | 34 (89) 2 (4) | 12 ? |